StockNews.AI
AIM
StockNews.AI
134 days

AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

1. AIM ImmunoTech is focusing on treating cancers and immune disorders. 2. Its stock trades under the ticker AIMI on the Pink Market. 3. A special meeting regarding a reverse split is scheduled for April 30, 2025. 4. Ampligen® is their lead investigational drug for multiple diseases. 5. The company warns investors about risks in forward-looking statements.

4m saved
Insight
Article

FAQ

Why Neutral?

The announcement of a reverse split often indicates financial restructuring, which can be neutral. Historical precedents show mixed market responses to such announcements without clear operational progress.

How important is it?

The news about the reverse split and ongoing developments positions AIM in a crucial time. The mixed sentiment surrounding the drug’s future adds to the importance score.

Why Short Term?

The upcoming reverse split meeting will have immediate implications on stock perception. However, longer-term outcomes depend on Ampligen®'s success in trials.

Related Companies

NVAXMRNAGILD
OCALA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) — an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19 — announced that as of today its common stock is trading under the ticker AIMI on the Pink Open Market and the Special Meeting on April 30, 2025, about a reverse split is still on. For additional information, refer to AIM’s Definitive Proxy Statement filed April 2, 2025. About AIM ImmunoTech Inc.AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a prophylactic or therapy for any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Related News